Advances in the genetics of progressive myoclonus epilepsy
- PMID: 11579433
- DOI: 10.1002/ajmg.1575
Advances in the genetics of progressive myoclonus epilepsy
Abstract
The genetic progressive myoclonus epilepsies (PMEs) are clinically characterized by the triad of stimulus sensitive myoclonus (segmental lightning like muscular jerks), epilepsy (grand mal and absences) and progressive neurologic deterioration (dementia, ataxia, and various neurologic signs depending on the cause). Etiologically heterogenous, PMEs are rare and mostly autosomal recessive disorders, with the exception of autosomal dominant dentatorubral-pallidoluysian atrophy and mitochondrial encephalomyopathy with ragged red fibers (MERRF). In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA). In this review, we cover mainly these rapid advances.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
The molecular genetic bases of the progressive myoclonus epilepsies.Adv Neurol. 1999;79:383-98. Adv Neurol. 1999. PMID: 10514828 Review.
-
The autosomal recessively inherited progressive myoclonus epilepsies and their genes.Epilepsia. 2009 May;50 Suppl 5:29-36. doi: 10.1111/j.1528-1167.2009.02117.x. Epilepsia. 2009. PMID: 19469843 Review.
-
Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects.Lancet Neurol. 2005 Apr;4(4):239-48. doi: 10.1016/S1474-4422(05)70043-0. Lancet Neurol. 2005. PMID: 15778103 Review.
-
Progressive myoclonic epilepsy.Neurol India. 2010 Jul-Aug;58(4):514-22. doi: 10.4103/0028-3886.68660. Neurol India. 2010. PMID: 20739785 Review.
-
Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B.Adv Neurol. 2005;95:47-57. Adv Neurol. 2005. PMID: 15508913 Review. No abstract available.
Cited by
-
Wasteosomes (corpora amylacea) as a hallmark of chronic glymphatic insufficiency.Proc Natl Acad Sci U S A. 2022 Nov 29;119(48):e2211326119. doi: 10.1073/pnas.2211326119. Epub 2022 Nov 21. Proc Natl Acad Sci U S A. 2022. PMID: 36409907 Free PMC article.
-
Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.J Hum Genet. 2005;50(7):347-352. doi: 10.1007/s10038-005-0263-7. Epub 2005 Jul 15. J Hum Genet. 2005. PMID: 16021330
-
A bioassay for Lafora disease and laforin glucan phosphatase activity.Clin Biochem. 2013 Dec;46(18):1869-76. doi: 10.1016/j.clinbiochem.2013.08.016. Epub 2013 Sep 6. Clin Biochem. 2013. PMID: 24012855 Free PMC article.
-
Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease.J Biosci. 2015 Dec;40(5):863-71. doi: 10.1007/s12038-015-9570-0. J Biosci. 2015. PMID: 26648032
-
Advances in lafora progressive myoclonus epilepsy.Curr Neurol Neurosci Rep. 2007 Sep;7(5):428-33. doi: 10.1007/s11910-007-0066-7. Curr Neurol Neurosci Rep. 2007. PMID: 17764634 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous